Morgan Stanley Nanobiotix S.A. Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
A detailed history of Morgan Stanley transactions in Nanobiotix S.A. stock. As of the latest transaction made, Morgan Stanley holds 5,300 shares of NBTX stock, worth $39,220. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,300
Previous 6,100
13.11%
Holding current value
$39,220
Previous $21,000
19.05%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding NBTX
# of Institutions
11Shares Held
5.88MCall Options Held
0Put Options Held
0-
Johnson & Johnson New Brunswick, NJ5.62MShares$41.6 Million8.95% of portfolio
-
Black Rock Inc. New York, NY239KShares$1.77 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA10.2KShares$75,3610.0% of portfolio
-
Ubs Group Ag4.42KShares$32,6930.0% of portfolio
-
Ever Source Wealth Advisors, LLC517Shares$3,8250.0% of portfolio
About Nanobiotix S.A.
- Ticker NBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,875,900
- Market Cap $258M
- Description
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...